Ongoing Research Projects

MonovalentBA 4/5 Fase 1,2/3

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS- CoV-2 Variant (BA.4/5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have Completed the Full Vaccination

M72 TB
Vaccine

A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults

RECOGNISE

Real-world effectiveness of ChAdOx-1s, CoronaVac, BBIBP CorV, mRNA-1273, and BNT162b2 in Jakarta: test-negative design study based in existing health care data sources

Monovalent
Phase-1

A Randomized, Double-Blind, and Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant mRNA Vaccines (ABO1009-DP and ABO-CoV.617.2) in Indonesian Subjects Aged 18 Years and Older Who Have Not Received SARS-CoV-2 Vaccines

PREATTRI

Pretreatment Attrition in People with Drug-Resistant Tuberculosis

PRIMA-4TB

The Usage of Rifapentine, Isoniazid, Pyrazinamide, and Moxifloxacin Combination for 4 months for Drug-Sensitive Tuberculosis Patients in Indonesia

Vax TB Inhale Phase-1

Randomized, observer-blind study to evaluate the safety and immunogenicity of a viral vector-based Tuberculosis (TB) vaccine (Ad5-105K) in healthy people aged 6 years and above

TRUST-INA

Truncate Strategy for Drug-sensitive Tuberculosis in Indonesia

Pneumococcal
Invasive

Clinical Characteristics and Serotype Distribution in Patient Hospitalized with Invasive Pneumococcal Disease

1 to 3

A Randomized Trial Comparing Treatment Completion of Daily Rifapentine & Isoniazid for One Month (1HP) to Weekly Rifapentine & Isoniazid for 3 Months (3HP) in Persons Living with HIV and in HIV-Negative Household Contacts of Recently Diagnosed Tuberculosis Patients

BGSI

Human Genomic Analysis and Mycobacterium Tuberculosis in Cases of Drug-Sensitive and Drug-Resistant Pulmonary TB in Indonesia

Tongue
Swab

Evaluating next generation LAM assays and molecular diagnostics (near POC and low complexity NAATs) for the diagnosis of TB among people with presumptive TB: a prospective multicentre diagnostic accuracy study

Vit C Zinc

Effectiveness of Vitamin C and Zinc as Adjuvant Therapy for Tuberculosis on MTB Culture Conversion

RAIT Study

A Pulmonary Tuberculosis Prediction Using CAD4TB Artificial Intelligence (Computer-Aided Detection for Tuberculosis) Based on Thoracic X-Ray Photos among Indonesian Subjects

ARCoV-005

A Global, Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older

Proxaluta
mide

A Randomized, Double-blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects

ONWARDS

Aims to support the national program by accelerating the implementation of the BPaL/M regimen as an alternative treatment for drug‑resistant TB patients in Indonesia, by aligning implementation at provincial and district/city levels and strengthening the capacity of health workers and stakeholder support.

The
Pharmaceutical Resilience
Roadmap Study

A descriptive qualitative policy analysis examining Indonesia’s pharmaceutical industry ecosystem to develop a roadmap for national self-reliance and resilience in the production of essential medicines for AIDS, Tuberculosis, and Malaria (ATM).

COBAS
MTB

A collaboration Study with Roche Molecular Systems, Inc. that aims to assess the analytical and clinical performance of an investigational device under real-world conditions.

INHALVAX

A phase I randomized, double-blind, placebo-controlled and doseescalation study to evaluate the safety and immunogenicity of a viral vectorbased Tuberculosis (TB) vaccine Ad5-105K against TB Disease in adults aged 18 to 49 years

ELIMINATE

Elimination of TB and Leprosy through Integrated Systematic Screening Efforts

DriveDx4TB
TOO

Evaluating next generation LAM assays and molecular diagnostics [near Point of Care (POC) and low complexity nucleic acid amplification tests (NAATs)] for the diagnosis of TB among people with presumptive TB: a prospective multicentre diagnostic accuracy study.

Clinical validation for lung cancer screening by ctDNA The SPOT-MAS LUNG Clinical Validation Study

VIZI-TB

This study aims to evaluate the effectiveness of supplementing vitamin C (500 mg) and zinc (10 mg) as an adjunct to standard therapy in participants with newly diagnosed drug-sensitive pulmonary tuberculosis.

LUNGCARE

INTRO-TB-VAX

Investigating a Novel Targeted ROllout strategy for adult and adolescent TB Vaccines for mAXimum impact